Education
About Us
Working with TipRanks
Follow Us
Palvella Therapeutics, Inc. (PVLA)
NASDAQ:PVLA
PVLA Analyst Ratings
Strong Buy
14 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PVLA Stock 12 Month Forecast
Average Price Target
$184.19
▲(115.02% Upside)
| Highest Price Target$212.00 | Average Price Target$184.19 | Lowest Price Target$76.43 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Craig-Hallum
$175→$205
Buy
139.32%
Upside
Reiterated
02/18/26
Mizuho Securities
$205
Buy
139.32%
Upside
Reiterated
02/17/26
Stifel Nicolaus
$145→$180
Buy
110.13%
Upside
Reiterated
02/13/26
LifeSci Capital
$150
Buy
75.11%
Upside
Reiterated
02/12/26
H.C. Wainwright
$200
Buy
133.48%
Upside
Reiterated
02/09/26
Canaccord Genuity
$204→$76.43
Buy
-10.78%
Downside
Reiterated
02/05/26
TD Cowen
$133→$190
Buy
121.81%
Upside
Reiterated
02/02/26
BTIG
$192
Buy
124.14%
Upside
Reiterated
01/29/26
Truist Financial
―
Buy
―
Reiterated
01/16/26
Cantor Fitzgerald
$200→$210
Buy
145.16%
Upside
Reiterated
12/15/25
Chardan Capital
$110→$174
Buy
103.13%
Upside
Reiterated
12/15/25
Oppenheimer
$120→$200
Buy
133.48%
Upside
Reiterated
12/15/25
Lucid Capital
$122→$212
Buy
147.49%
Upside
Reiterated
12/15/25
Raymond James
$92→$143
Buy
66.94%
Upside
Upgraded
11/19/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Craig-Hallum
$175→$205
Buy
139.32%
Upside
Reiterated
02/18/26
Mizuho Securities
$205
Buy
139.32%
Upside
Reiterated
02/17/26
Stifel Nicolaus
$145→$180
Buy
110.13%
Upside
Reiterated
02/13/26
LifeSci Capital
$150
Buy
75.11%
Upside
Reiterated
02/12/26
H.C. Wainwright
$200
Buy
133.48%
Upside
Reiterated
02/09/26
Canaccord Genuity
$204→$76.43
Buy
-10.78%
Downside
Reiterated
02/05/26
TD Cowen
$133→$190
Buy
121.81%
Upside
Reiterated
02/02/26
BTIG
$192
Buy
124.14%
Upside
Reiterated
01/29/26
Truist Financial
―
Buy
―
Reiterated
01/16/26
Cantor Fitzgerald
$200→$210
Buy
145.16%
Upside
Reiterated
12/15/25
Chardan Capital
$110→$174
Buy
103.13%
Upside
Reiterated
12/15/25
Oppenheimer
$120→$200
Buy
133.48%
Upside
Reiterated
12/15/25
Lucid Capital
$122→$212
Buy
147.49%
Upside
Reiterated
12/15/25
Raymond James
$92→$143
Buy
66.94%
Upside
Upgraded
11/19/25
Best Analysts Covering Palvella Therapeutics
3 Months
xxx
Success Rate
5/6 ratings generated profit
Average Return
+49.03%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +49.03% per trade.
1 Year
Success Rate
5/5 ratings generated profit
Average Return
+202.72%
reiterated a buy rating 7 months ago
Copying Louise Chen's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +202.72% per trade.
2 Years
xxx
Success Rate
5/5 ratings generated profit
Average Return
+202.72%
reiterated a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +202.72% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
PVLA Analyst Recommendation Trends
Rating
Oct 25
Nov 25
Dec 25
Jan 26
Feb 26
Strong Buy
9
13
22
26
27
Buy
18
21
16
19
10
Hold
0
0
1
22
22
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
27
34
39
67
59
Each month's total comprises the sum of three months' worth of ratings.
PVLA Financial Forecast
PVLA Stock Forecast FAQ
What is PVLA’s average 12-month price target, according to analysts?
Based on analyst ratings, Palvella Therapeutics, Inc.’s 12-month average price target is 184.19.
What is PVLA’s upside potential, based on the analysts’ average price target?
Palvella Therapeutics, Inc. has 115.02% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PVLA a Buy, Sell or Hold?
Palvella Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 14 buy ratings, 0 hold ratings and 0 sell ratings.
What is Palvella Therapeutics, Inc.’s price target?
The average price target for Palvella Therapeutics, Inc. is 184.19. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $212.00 ,the lowest forecast is $76.43. The average price target represents 115.02% Increase from the current price of $85.66.
The highest analyst price target is $212.00 ,the lowest forecast is $76.43. The average price target represents 115.02% Increase from the current price of $85.66.
What do analysts say about Palvella Therapeutics, Inc.?
Palvella Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
How can I buy shares of PVLA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.